Published 2025-02-01
“…Varis Ruamviboonsuk,1,2 Wijak Kongwattananon,1,3 Natthaya Chuaypen4 1Department of Ophthalmology,
King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok,
Thailand; 2Medical Science Program, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok,
Thailand; 3Center of Excellence in Retina, Department of Ophthalmology, Faculty of Medicine Chulalongkorn University and
King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok,
Thailand; 4Metabolic Diseases in Gut and Urinary System Research Unit (MeDGURU), Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok,
ThailandCorrespondence: Wijak Kongwattananon, Center of Excellence in Retina, Department of Ophthalmology, Faculty of Medicine Chulalongkorn University and
King Chulalongkorn Memorial Hospital, Thai Red Cross Society, 1873 Rama IV Road, Pathum Wan, Bangkok, 10330,
Thailand, Tel +662 256 4000, Email wijak.k@chula.ac.thPurpose: Intravitreal brolucizumab, approved for neovascular age-related macular degeneration (nAMD), may trigger immune responses leading to intraocular inflammation (IOI) by increasing pro-inflammatory cytokines. …”
Get full text
Article